Currently, palbociclib is being studied for application in early-stage ER-positive/HER2-negative breast cancer treatment, including adjuvant as well as neoadjuvant studies [100], and is also undergoing clinical trials for non-breast cancer diseases (https://clinicaltrials.gov/ accessed on 31 May 2021). Here, ERBB2 is linked to breast carcinoma.